Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6113917 | Transfusion and Apheresis Science | 2016 | 5 Pages |
Abstract
We investigated the course of 54 patients presenting with primary central nervous system lymphoma, who were treated in daily practice. The patients were treated with chemotherapy and/or radiotherapy and/or intrathecal chemotherapy. At a median follow-up period of 23 months (range 1-71), median relapse-free survival (RFS) and overall survival (OS) were not reached. Estimated 2-year RFS and OS rates were 42% and 48%, respectively. Ten relapsed PCNSL patients underwent ASCT. Complete remission rate of these patients was 40%, with 20% treatment-related mortality. Estimated 2-year RFS and OS rates were 37% and 40%, respectively. The prognosis of patients with PCNSL, who received off-study treatment, is still dismal.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Mehmet Ali Erkurt, Ilhami Berber, Emre Tekgündüz, Mehmet Hilmi Dogu, Serdal Korkmaz, Cengiz Demir, Mehmet Yilmaz, Olga Meltem Akay, CiÄdem Pala, Yusuf Bilen, Emin Kaya, Ismail Sari, Mehmet Sencan, Irfan Kuku, Fevzi AltuntaÅ, Mehmet Sinan Dal,